logo
AstroNova Reports First-Quarter Fiscal 2026 Revenue Grew 14% Driven by Double Digit Growth in Both Aerospace and Product Identification Segments

AstroNova Reports First-Quarter Fiscal 2026 Revenue Grew 14% Driven by Double Digit Growth in Both Aerospace and Product Identification Segments

Business Wire6 days ago

WEST WARWICK, R.I.--(BUSINESS WIRE)--AstroNova, Inc. (Nasdaq: ALOT), a global leader in data visualization technologies, today announced financial results for its fiscal 2026 first quarter ended April 30, 2025. Results include the May 6, 2024, acquisition of MTEX ('MTEX' or 'the acquisition') which has been fully integrated into the Product Identification ('Product ID') segment.
Greg Woods, President and Chief Executive Officer of AstroNova, stated, 'We are executing on our plan to drive growth and improve profitability. Early results were demonstrated in the first quarter as we delivered double-digit growth in the quarter from both segments, driven in part by the contribution of the acquisition, increasing commercial aircraft build rates, demand for digital color label and package printers, as well as shipments related to the recently announced defense contract renewal. We implemented approximately $1.9 million of our previously announced $3 million annualized cost reduction plan. In the second quarter, we expect to realize those reductions and to substantially complete the full cost reduction plan.'
Mr. Woods added, 'Importantly, we have made significant progress advancing the new foundational technology gained with the MTEX acquisition. We have re-engineered the acquired technology to incorporate a wide range of improvements that provide a more robust, next-generation print engine solution designed to enhance our customer's experience while reducing their total cost of ownership. In Product Identification, we expect the combination of our restructured sales organization under new leadership, combined with these highly innovative technological advancements, to gain traction in the market and drive hardware, supplies, and service revenue growth as we increase our installed base.'
First Quarter Fiscal 2026 Overview 2
Three Months Ended
April 30, 2025 April 27, 2024 $ Variance % Variance January 31, 2025 $ Variance % Variance
Gross Profit
$
12,652
$
11,972
$
680
5.7
%
$
12,737
$
(85
)
-0.7
%
Gross Profit Margin
33.6
%
36.3
%
34.1
%
Non-GAAP Gross Profit
$
13,053
$
11,972
$
1,081
9.0
%
$
12,799
$
254
2.0
%
Non-GAAP Gross Profit Margin
34.6
%
36.3
%
34.3
%
Operating Income (Loss)
$
571
$
1,346
$
(775
)
-57.6
%
$
(12,311
)
$
12,882
-104.6
%
Operating Margin
1.5
%
4.1
%
(33.0
)%
Non-GAAP Operating Income
$
1,527
$
1,346
$
181
13.4
%
$
1,408
$
119
8.4
%
Non-GAAP Operating Income Margin
4.0
%
4.1
%
3.8
%
Net Income (Loss)
$
(376
)
$
1,181
$
(1,557
)
-131.8
%
$
(15,600
)
$
15,224
-97.6
%
Non-GAAP Net Income
$
354
$
1,181
$
(827
)
-70.0
%
$
419
$
(65
)
-15.5
%
Adjusted EBITDA
$
3,148
$
2,465
$
683
27.7
%
$
2,793
$
355
12.7
%
Adjusted EBITDA Margin
8.3
%
7.5
%
7.5
%
Expand
Net revenue growth of $4.7 million reflected strength in both the Aerospace and Product Identification segments, which benefitted from a combination of drivers that delivered double digit growth in both segments. Foreign currency translation was a $0.6 million benefit in the quarter.
Gross profit was $12.7 million, or 33.6% of sales. Lower gross margin year-over-year reflects the margin dilution related to the acquisition and product mix.
Operating income was $0.6 million and operating margin for the quarter was 1.5%. On a non-GAAP basis, operating income 2 increased 13.4% or $0.2 million compared with the first quarter of the prior year. The improvement, which excludes inventory step-up, acquisition and restructuring expenses, was the result of improved operating performance by the Aerospace segment offset by a $1.6 million increase in corporate expenses. The increase in corporate expenses was primarily the result of increased healthcare costs and higher professional fees. Sequentially, adjusted operating income improved 8.4% on relatively similar revenue, reflecting cost containment efforts and early impacts of the restructuring.
Interest expense increased $0.4 million to $0.9 million on higher balances and higher rates related to the financing for the acquisition.
Net loss was $0.4 million, or a loss of $0.05 per diluted share, compared with net income of $1.2 million, or $0.15 per diluted share. Non-GAAP net income was $0.4 million, or $0.05 per diluted share. There were no adjustments in the prior-year period. Net profit margin for the fiscal 2026 first quarter was (1.0)% compared with 3.6% and (41.8)% for the first and fourth quarters of fiscal 2025, respectively. Adjusted EBITDA of $3.1 million increased 27.6% compared with the prior-year period and grew 28% compared with the trailing fourth quarter of fiscal 2025. Adjusted EBITDA margin for the fiscal 2026 first quarter expanded 80 basis points both year-over-year and sequentially.
Product Identification Segment Review
Product ID revenue was $26.3 million for the first quarter of fiscal 2026 compared with $23.2 million for the first quarter of fiscal 2025, an increase of 13.4% or $3.1 million. The contribution of $1.4 million from the acquisition, increased demand for legacy desktop label printers of $1.3 million and shipments of $0.4 million of mail & sheet printers out of backlog drove the increase.
Operating income for Product ID was $2.8 million compared with $3.0 million in the prior-year period. Operating margin was 10.6% compared with 12.9% in the prior year period. Non-GAAP segment operating income increased $0.1 million, or 4.4% to $3.1 million after adjusting for $0.3 million of restructuring charges and $0. 1 million related inventory step-up expenses. Non-GAAP operating margin for the first quarter of fiscal 2026 was 11.9%.
Aerospace Segment Review
Aerospace segment revenue was $11.4 million for the first quarter of fiscal 2026 compared with $9.8 million for the first quarter of fiscal 2025, an increase of 16.8%, or $1.6 million. Growth was driven by increased shipments of ToughWriter ® products for both the commercial and defense markets.
Aerospace segment operating profit was $2.8 million, up $1.0 million or 60.5% from the prior year first quarter, based on higher volume.
Balance Sheet and Liquidity
Cash at the end of the first quarter of fiscal 2026 was $5.4 million, up $0.3 million from the end of fiscal 2025. The Company paid down $3.7 million in debt, comprised of principal on the term loan and borrowings under its revolving credit facility in the first quarter of fiscal 2026. The Company was in compliance with the covenants of its lending agreement at the end of the quarter.
Cash provided by operations in the fiscal 2026 first quarter was $4.4 million, down from $6.9 million in the prior year period. The decline was driven primarily by the timing associated with bulk replenishment of legacy ink, printheads, and media supplies, amounting to $3.0 million. The Company is executing on a plan to improve inventory turns to 3x from current levels of approximately 2x.
Capital expenditures required $60 thousand in the quarter and are expected to be less than $2 million for fiscal 2026.
Orders, Backlog and Fiscal 2026 Outlook
Orders in the first quarter of fiscal 2026 were $34.9 million, up from $33.1 million in the first quarter of fiscal 2025. The Company's order backlog was $25.5 million as of April 30, 2025, compared with $28.3 million at the end of fiscal 2025.
Mr. Woods noted, 'We expect to benefit from a number of factors as we advance through fiscal 2026 and beyond. These tailwinds include the following:
The multi-year backlogs at commercial aircraft OEMs whose build rates are expected to grow over the next few years
The Aerospace transition from legacy equipment to our ToughWriter ® models which will support proprietary aftermarket revenue growth
The measurable expansion of the total addressable market for our Product Identification segment driven by the new next-generation wider format, higher volume printer solutions we now offer as a result of the MTEX acquisition
The seven significant new product launches planned for fiscal 2026, of which three have been completed
In addition, we expect margin improvement given our restructuring efforts and the streamlining of the organization. And, looking further ahead, we will benefit significantly from the approximately $4 million reduction in royalty payments in fiscal 2028.'
For fiscal 2026, AstroNova continues to expect net revenue in the range of $160 million to $165 million, which is a 7% increase over fiscal 2025 at the mid-point of the range. Adjusted EBITDA margin is expected to be in the range of 8.5% to 9.5%, an 80-basis point expansion over the prior year at the mid-point. The Company's expected effective tax rate for fiscal 2026 is approximately 25% and depreciation and amortization are expected to be approximately $5 million.
Earnings Conference Call Information
AstroNova will host a conference call and webcast today at 9:00 a.m. ET to review financial and operating results for the first quarter fiscal 2026. A question and answer session will follow.
To access the conference call, please dial (201) 689-8560 or find the webcast and accompanying slide presentation at investors.astronovainc.com.
A telephonic replay will be available from 12:00 p.m. ET on the day of the call through Thursday, June 19, 2025. To listen to the archived call, dial (412) 317-6671 and enter a replay PIN 13753559. The webcast replay will be available on the Investor Relations section of the Company's website where a transcript will be posted once available.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this news release contains the Non-GAAP financial measures: Non-GAAP gross profit, Non-GAAP gross profit margin, Non-GAAP operating expenses, Non-GAAP operating income, Non-GAAP operating income margin, Non-GAAP net income, Non-GAAP net income per Common Share - diluted , Non-GAAP segment gross profit, Non-GAAP segment gross profit margin, Non-GAAP segment operating income, Non-GAAP segment operating income margin Adjusted EBITDA, and Adjusted EBITDA Margin. AstroNova believes that the inclusion of these Non-GAAP financial measures helps investors gain a meaningful understanding of changes in the Company's core operating results and can help investors who wish to make comparisons between AstroNova and other companies on both a GAAP and a Non-GAAP basis. AstroNova's management uses these Non-GAAP financial measures, in addition to GAAP financial measures, as the basis for measuring its core operating performance and comparing such performance to that of prior periods and to the performance of its competitors. These measures are also used by the Company's management to assist with their financial and operating decision-making. Please refer to the financial reconciliation table included in this news release for a reconciliation of the Non-GAAP measures to the most directly comparable GAAP measures for the three months ended April 30, 2025, January 31, 2025 and April 27, 2024.
AstroNova has not reconciled the forward-looking Adjusted EBITDA growth percentage included in its fiscal 2026 financial targets and outlook to the most directly comparable forward-looking GAAP measure because this cannot be done without unreasonable effort due to the lack of predictability regarding cost of sales, operating expenses, depreciation and amortization, and stock-based compensation. The impact of any of these items, individually or in the aggregate, may be significant.
About AstroNova
AstroNova (Nasdaq: ALOT), a global leader in data visualization technologies since 1969, designs, manufactures, distributes and services a broad range of products that acquire, store, analyze, and present data in multiple formats.
The Product Identification segment provides a wide array of digital, end-to-end product marking and identification solutions, including hardware, software, and supplies for OEMs, commercial printers, and brand owners. The Aerospace segment provides products designed for airborne printing solutions, avionics, and data acquisition. Our aerospace products include flight deck printing solutions, networking hardware, and specialized aerospace-grade supplies. Our data acquisition systems are used in research and development, flight testing, missile and rocket telemetry, high precision production and power monitoring, and maintenance applications.
AstroNova is a member of the Russell Microcap ® Index and the LD Micro Index (INDEXNYSEGIS: LDMICRO). Additional information is available by visiting https://astronovainc.com/.
Forward-Looking Statements
Information included in this news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact but rather reflect our current expectations concerning future events and results. These statements may include the use of the words 'believes,' 'expects,' 'intends,' 'plans,' 'anticipates,' 'likely,' 'continues,' 'may,' 'will,' and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning the Company's anticipated performance, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, (i) the risk that our organizational improvements at MTEX may not result in the benefits that we expect; (ii) the risk that our cost-reduction and product line rationalization initiative may not provide the expected benefits; (iii) the risk that our Aerospace customers may not increase their build rates as much as we expect or convert to our ToughWriter ® line in the volumes or on the schedule that we expect; (iv) the risk that the addressable market for our Product Identification products may not expand as much as we expect, (v) the risk that we may not realize the anticipated benefits of our next-generation print engine technology; and (vi) those factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2025 and subsequent filings AstroNova makes with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The reader is cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this news release.
ASTRONOVA, INC.
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
April 30, 2025 January 31, 2025
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents
$
5,353
$
5,050
Accounts Receivable, net
21,365
21,218
Inventories, net
51,457
47,894
Prepaid Expenses and Other Current Assets
3,006
3,855
Total Current Assets
81,181
78,017
PROPERTY, PLANT AND EQUIPMENT
63,050
62,361
Less Accumulated Depreciation
(45,530
)
(44,722
)
Property, Plant and Equipment, net
17,520
17,639
OTHER ASSETS
Identifiable Intangibles, net
23,414
23,519
Goodwill
15,232
14,515
Deferred Tax Assets, net
8,527
8,431
Right of Use Asset
2,763
1,781
Other Assets
1,687
1,693
TOTAL ASSETS
$
150,324
$
145,595
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts Payable
$
11,383
$
7,928
Accrued Compensation
4,878
3,745
Other Accrued Expenses
4,165
4,461
Revolving Line of Credit
18,370
20,929
Current Portion of Long-Term Debt
6,041
6,110
Short-Term Debt
327
581
Current Liability – Royalty Obligation
1,233
1,358
Current Liability – Excess Royalty Payment Due
580
691
Deferred Revenue
1,666
543
Total Current Liabilities
48,643
46,346
NON-CURRENT LIABILITIES
Long-Term Debt, net of current portion
20,002
19,044
Lease Liabilities, net of current portion
2,318
1,535
Grant Deferred Revenue
1,144
1,090
Royalty Obligation, net of current portion
982
1,106
Income Tax Payables
684
684
Deferred Tax Liabilities
-
40
TOTAL LIABILITIES
73,773
69,845
SHAREHOLDERS' EQUITY
Common Stock
550
547
Additional Paid-in Capital
64,569
64,215
Retained Earnings
49,004
49,380
Treasury Stock
(35,198
)
(35,043
)
Accumulated Other Comprehensive Loss, net of tax
(2,374
)
(3,349
)
TOTAL SHAREHOLDERS' EQUITY
76,551
75,750
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
$
150,324
$
145,595
Expand
ASTRONOVA, INC.
Condensed Consolidated Statements of Cash Flow
(In Thousands)
(Unaudited)
Three Months Ended
April 30, 2025 April 27, 2024
Cash Flows from Operating Activities:
Net Income (Loss)
$
(376
)
$
1,181
Adjustments to Reconcile Net Income (Loss) to Net Cash Provided by Operating Activities:
Depreciation and Amortization
1,290
911
Grant Income charged to Depreciation
56

Amortization of Debt Issuance Costs
8
6
Share-Based Compensation
306
325
Deferred Income Tax provision (Benefit)
(52
)

Changes in Assets and Liabilities:
Accounts Receivable
210
5,130
Inventories
(2,704
)
1,117
Income Taxes
172
(532
)
Accounts Payable and Accrued Expenses
3,622
(1,213
)
Deferred Revenue
1,041
(183
)
Other
822
162
Net Cash Provided by Operating Activities
4,395
6,904
Cash Flows from Investing Activities:
Purchases of Property, Plant and Equipment
(60
)
(492
)
Net Cash Used by Investing Activities
(60
)
(492
)
Cash Flows from Financing Activities:
Net Cash Proceeds from Employee Stock Option Plans
-
18
Net Cash Proceeds from Share Purchases under Employee Stock Purchase Plan
51
30
Net Cash Used for Payment of Taxes Related to Vested Restricted Stock
(155
)
(432
)
Repayments under Revolving Credit Facility
(2,872
)
(5,500
)
Payment of Minimum Guarantee Royalty Obligation
(428
)
(375
)
Principal Payments of Long-Term Debt
(826
)
(710
)
Net Cash Used for Financing Activities
(4,230
)
(6,969
)
Effect of Exchange Rate Changes on Cash and Cash Equivalents
198
20
Net (Decrease) Increase in Cash and Cash Equivalents
303
(537
)
Cash and Cash Equivalents, Beginning of Period
5,050
4,527
Cash and Cash Equivalents, End of Period
$
5,353
$
3,990
Supplemental Information:
Cash Paid (Received) During the Period for:
Interest
$
770
$
409
Income Taxes, net of refunds
$
(100
)
$
93
Non-Cash Transactions:
Operating Lease Obtained in Exchange for Operating Lease Liabilities
$
936
$
358
Expand
ASTRONOVA, INC.
Segment Sales and Profit
(Unaudited, $ in thousands)
Three Months
Ended
($ in thousands) April 30, 2025 April 27, 2024
Revenue:
Product Identification
$
26,289
$
23,185
Aerospace
11,419
9,776
Total Revenue
$
37,708
$
32,961
Gross Profit:
Product Identification
$
8,727
$
8,326
Aerospace
3,925
3,646
Gross Profit
$
12,652
$
11,972
Gross Profit Margin:
Product Identification
33.2
%
35.9
%
Aerospace
34.4
%
37.3
%
Gross Profit Margin
33.6
%
36.3
%
Segment Operating Income:
Product Identification
$
2,791
$
2,991
Aerospace
2,764
1,722
Total Segment Operating Income
$
5,555
$
4,713
Segment Operating Margin:
Product Identification
10.6
%
12.9
%
Aerospace
24.2
%
17.6
%
Total Segment Operating Margin
14.7
%
14.3
%
Corporate Expense
(4,984
)
(3,367
)
Operating Income
$
571
$
1,346
Interest Expense
$
897
$
482
Other (Income)/Expense, net
(25
)
117
Income (Loss) Before Income Taxes
$
(301
)
$
747
Income Tax Provision (Benefit)
75
(434
)
Net Income (Loss)
$
(376
)
$
1,181
Expand
ASTRONOVA, INC.
Segment Sales and Non-GAAP Profit
(Unaudited, $ in thousands)
Three Months
Ended
($ in thousands) April 30, 2025 April 27, 2024
Revenue:
Product Identification
$
26,289
$
23,185
Aerospace
11,419
9,776
Total Revenue
$
37,708
$
32,961
Non-GAAP Gross Profit:
Product Identification
$
8,961
$
8,326
Aerospace
4,092
3,646
Non-GAAP Gross Profit
$
13,053
$
11,972
Non-GAAP Gross Profit Margin:
Product Identification
34.1
%
35.9
%
Aerospace
35.8
%
37.3
%
Non-GAAP Gross Profit Margin
34.6
%
36.3
%
Non-GAAP Segment Operating Income:
Product Identification
$
3,120
$
2,991
Aerospace
2,932
1,722
Total Non-GAAP Segment Operating Income
$
6,052
$
4,713
Non-GAAP Segment Operating Margin:
Product Identification
11.9
%
12.9
%
Aerospace
25.7
%
17.6
%
Total Non-GAAP Segment Operating Margin
16.0
%
14.3
%
Expand
ASTRONOVA, INC.
Revenue by Market
(unaudited, $ in thousands)
Product Identification: Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY2025 Q1 FY26
Desktop Label Printers
$
14,220
$
16,349
$
15,408
$
14,019
$
59,996
$
15,478
Professional Label Printers
3,245
4,231
3,423
2,972
13,872
3,247
Direct to Package/Overprint Printers
1,787
2,925
3,627
2,718
11,057
3,396
Mail & Sheet/Flat Pack Printers
3,930
3,471
3,679
4,494
15,574
4,050
Flexible Packaging Printers
0
0
15
1,289
1,304
30
Other
3
188
165
187
542
88
TOTAL
$
23,185
$
27,165
$
26,317
$
25,679
$
102,345
26,289
Aerospace: Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY2025 Q1 FY26
Defense
$
329
$
608
$
734
$
781
$
2,452
$
2,502
Commercial Aircraft
3,813
6,299
5,221
4,363
19,696
3,444
Regional and Biz Jet Aircraft
697
604
993
802
3,096
251
Aftermarket
4,694
5,326
7,059
5,481
22,559
4,869
Other
243
537
99
255
1,134
352
TOTAL
$
9,776
$
13,374
$
14,105
$
11,683
$
48,938
$
11,419
Consolidated Total
$
32,961
$
40,539
$
40,422
$
37,361
$
151,283
$
37,708
Expand
ASTRONOVA, INC.
Revenue by Type
(Unaudited, $ in thousands)
Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY 2025 Q1 FY26
Product ID Hardware
$
3,802
$
4,311
$
4,590
$
5,591
$
18,294
$
4,776
Product ID Recurring Supplies, Parts & Service
19,383
22,854
21,727
20,087
84,051
21,513
Total Product ID
$
23,185
$
27,165
$
26,317
$
25,678
$
102,345
$
26,289
Aerospace Hardware
$
5,073
$
8,048
$
7,032
$
6,185
$
26,338
$
6,519
Aerospace Recurring Supplies, Parts & Service
4,703
5,326
7,073
5,498
22,600
4,900
Total Aerospace
$
9,776
$
13,374
$
14,105
$
11,683
$
48,938
$
11,419
AstroNova Hardware
$
8,875
$
12,359
$
11,622
$
11,776
$
44,632
$
11,295
AstroNova Recurring Supplies, Parts & Service
24,086
28,180
28,800
25,585
106,651
26,413
TOTAL
$
32,961
$
40,539
$
40,422
$
37,361
$
151,283
$
37,708
Expand
ASTRONOVA, INC.
Reconciliation of GAAP to Non-GAAP Items
(Unaudited, $ in thousands)
Three Months Ended
April 30, 2025 April 27, 2024
Revenue
$
37,708
$
32,961
Gross Profit
$
12,652
$
11,972
Inventory Step-Up
61
-
Restructuring Charges
340
-
Non-GAAP Gross Profit
$
13,053
$
11,972
Gross Profit Margin
33.6
%
36.3
%
Non-GAAP Gross Profit Margin
34.6
%
36.3
%
Operating Expenses
$
12,081
$
10,626
MTEX-related Acquisition Expenses
(337
)
-
Restructuring Charges
(218
)
-
Non-GAAP Operating Expenses
$
11,526
$
10,626
Operating Income
$
571
$
1,346
MTEX-related Acquisition Expenses
337
-
Inventory Step-Up
61
-
Restructuring Charges
558
-
Non-GAAP Operating Income
$
1,527
$
1,346
Operating Income Margin
1.5
%
4.1
%
Non-GAAP Operating Income Margin
4.0
%
4.1
%
Net Income (Loss)
$
(376
)
$
1,181
MTEX-related Acquisition Expenses (1)
257
-
Inventory Step-Up (1)
49
-
Restructuring Charges (1)
424
-
Non-GAAP Net Income
$
354
$
1,181
Net Income (Loss) per Common Share - Diluted
$
(0.05
)
$
0.15
MTEX-related Acquisition Expenses (1)
0.03
-
Inventory Step-Up (1)
0.01
-
Restructuring Charges (1)
0.06
-
Non-GAAP Net Income per Common Share - Diluted
$
0.05
$
0.15
(1) Net of taxes
Expand
ASTRONOVA, INC.
Reconciliation of Net Income and Margin to Adjusted EBITDA and Margin
(Unaudited, $ in thousands)
Three Months Ended
April 30, 2025 April 27, 2024
Net Income (Loss)
$
(376
)
$
1,181
Interest Expense
897
482
Income Tax Expense (Benefit)
75
(434
)
Depreciation & Amortization
1,290
911
EBITDA
$
1,886
$
2,141
Share-Based Compensation
306
325
MTEX-related Acquisition Expenses
337
-
Inventory Step-Up
61
-
Restructuring Charges
558
-
Adjusted EBITDA
$
3,148
$
2,465
Revenue
37,708
32,961
Net Income (Loss) Margin
-1.0
%
3.6
%
Adjusted EBITDA Margin
8.3
%
7.5
%
Expand
ASTRONOVA, INC.
Reconciliation of Segment Operating Profit and Margin to Non-GAAP Operating Profit and Margin
(Unaudited, $ in thousands)
Three Months Ended
April 30, 2025 April 27, 2024
Product
Identification
Aerospace Total
Product
Identification
Aerospace Total
Segment Operating Income
$
2,791
$
2,764
$
5,555
$
2,991
$
1,722
$
4,713
Inventory Step-Up
61
-
61
-
-
-
Restructuring Charges
268
168
436
-
-
-
Non-GAAP - Segment Operating Income
$
3,120
$
2,932
$
6,052
$
2,991
$
1,722
$
4,713
Operating Margin
10.6
%
24.2
%
14.7
%
12.9
%
17.6
%
14.3
%
Non-GAAP Operating Margin
11.9
%
25.7
%
16.0
%
12.9
%
17.6
%
14.3
%
Note: Segment Operating Income excludes General & Administrative Expenses
Expand

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nucor (NUE) Exceeds Market Returns: Some Facts to Consider
Nucor (NUE) Exceeds Market Returns: Some Facts to Consider

Yahoo

time36 minutes ago

  • Yahoo

Nucor (NUE) Exceeds Market Returns: Some Facts to Consider

In the latest market close, Nucor (NUE) reached $124.68, with a +1.75% movement compared to the previous day. This move outpaced the S&P 500's daily gain of 0.55%. On the other hand, the Dow registered a gain of 0.25%, and the technology-centric Nasdaq increased by 0.63%. Prior to today's trading, shares of the steel company had gained 2.01% over the past month. This has lagged the Basic Materials sector's gain of 4.58% and the S&P 500's gain of 6.29% in that time. The investment community will be closely monitoring the performance of Nucor in its forthcoming earnings report. In that report, analysts expect Nucor to post earnings of $2.21 per share. This would mark a year-over-year decline of 17.54%. Meanwhile, our latest consensus estimate is calling for revenue of $8.28 billion, up 2.55% from the prior-year quarter. For the full year, the Zacks Consensus Estimates project earnings of $7.88 per share and a revenue of $31.48 billion, demonstrating changes of -11.46% and +2.43%, respectively, from the preceding year. Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Nucor. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Nucor currently has a Zacks Rank of #3 (Hold). Investors should also note Nucor's current valuation metrics, including its Forward P/E ratio of 15.54. This valuation marks a premium compared to its industry's average Forward P/E of 10.69. Investors should also note that NUE has a PEG ratio of 0.78 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Steel - Producers industry was having an average PEG ratio of 0.94. The Steel - Producers industry is part of the Basic Materials sector. This industry currently has a Zacks Industry Rank of 68, which puts it in the top 28% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nucor Corporation (NUE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo

time37 minutes ago

  • Yahoo

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., June 11, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 shares of common stock and 57,740 restricted stock units ("RSUs") to 10 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $48.98 per share, Mirum's closing trading price on June 10, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder. To learn more about Mirum, visit and follow Mirum on Facebook, LinkedIn, Instagram and X. View source version on Contacts Investor Contact: Andrew McKibbenir@ Media Contact: Erin Murphymedia@

Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither
Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither

Yahoo

time42 minutes ago

  • Yahoo

Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither

A highly public feud between Tesla Inc (NASDAQ:TSLA) CEO Elon Musk and President Donald Trump took the world by storm last week and sent shares of the electric vehicle company lower. As the feud continues on, here's a look at where Benzinga readers stand. What Happened: A back-and-forth between Musk and Trump across social media platforms saw the two well-known individuals escalate a feud related to differences on the "Big Beautiful Bill." Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — The feud comes after Musk left his White House position working for the Department of Government Efficiency to spend more time working on his other companies, such as Tesla. Benzinga recently asked readers who they side with in the battle, which includes Musk criticizing the new debt the country will take on if the bill that Trump supports is passed by Congress. "In the feud between Donald Trump and Elon Musk, who are you more likely to publicly support?" Benzinga asked. Here are the results: Neither: 44% Elon Musk: 25% Donald Trump: 17% Both: 14% The poll found that a near majority said they would publicly support neither Trump or Musk in the feud between former friends. Of the two well-known candidates, Musk received the largest support with 25% of the poll, ranking ahead of Trump at 17%.Why It's Important: Over the weekend, the battle between Musk and Trump minimized some with the Tesla CEO deleting some of his tweets that brought some claims against the current president. Tweets about ending the SpaceX Dragon program were also deleted. A battle between Trump and Musk over the long run could see many losers, including the country's space program and the launch of robotaxis, with Musk a leader in both sectors and Trump able to slow down progress made by the billionaire. Tesla stock saw its largest one-day market capitalization drop last week on the heels of the feud. Tesla stock trades up 1.61% at $299.72 at publication on Monday versus a 52-week trading range of $167.42 to $488.54. The stock has fallen 15% over the last five days and is down 22% year-to-date in 2025. Read Next: Are you rich? Here's what Americans think you need to be considered wealthy. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? The study was conducted by Benzinga from June 5, 2025, through June 9, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 259 adults. Photo: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither originally appeared on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store